Advanced glycation end products downregulates peroxisome proliferator-activated receptor γ expression in cultured rabbit chondrocyte through MAPK pathway

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 108-114

  Yang, Qingshan ^a,b   Chen, Cheng ^a,c   Wu, Shujin ^a   Zhang, Ying ^c   Mao, Xinzhan ^a   Wang, Wanchun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Gan Su Province Hospital   (China)

^c No 163 Central Hospital of PLA   (China)

Author keywords

Advanced glycation end products; Chondrocyte; Mitogen activated protein kinases; Peroxisome proliferator activated receptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADVANCED GLYCATION END PRODUCT; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; COLLAGENASE 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CARTILAGE CELL; CELL DAMAGE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 13; OSTEOARTHRITIS; PPAR GAMMA; PROTEIN KINASE INHIBITORS; RABBITS; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM ALBUMIN, BOVINE; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049307983     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.025     Document Type: Article

References (33)

1. Afif H., Benderdour M., Mfuna-Endam L., Martel-Pelletier J., Pelletier J.P., Duval N., Fahmi H. Peroxisome proliferator-activated receptor γ1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1γ in articular chondrocytes. Arthritis Res. Ther. 2007, 9:R31.
2. Anderson J.J., Felson D.T. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey, HANES (I): evidence for an association with overweight, race, and physical demands of work. Am. J. Epidemiol. 1988, 128:179-189.
3. Bagge E., Bjelle A., Eden S., Svanborg A. Factors associated with radiographic osteoarthritis: results from the population study 70-year-old people in Goteborg. J. Rheumatol. 1991, 118:1218-1222.
4. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 2006, 116:590-597.
5. Bordji K., Grillasca J.P., Gouze J.N., Magdalou J., Schohn H., Keller J.M., Bianchi A., Dauca M., Netter P., Terlain B. Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. J. Biol. Chem. 2000, 275:12243-12250.
6. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors, (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
7. Cecil D.L., Johnson K., Rediske J., Lotz M., Schmidt A.M., Terkeltaub R. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J. Immunol. 2005, 175:8296-8302.
8. Chen A.C., Temple M.M., Ng D.M., Verzijl N., DeGroot J., TeKoppele J.M., Sah R.L. Induction of advanced glycation end products and alterations of the tensile. Properties of articular cartilage. Arthritis Rheum. 2002, 46:3212-3217.
9. Corvol M.T., Dumontier M.F., Rappaport R. Culture of chondrocytes from the proliferative zone of epiphyseal growth plate cartilage from prepubertal rabbits. Biomedicine 1975, 23:103-107.
10. Creamer P., Hochberg M.C. Osteoarthritis. Lancet 1997, 350:503-508.
11. DeGroot J. The AGE of the matrix: chemistry, consequence and cure. Curr. Opin. Pharmacol. 2004, 4:301-305.
12. Fahmi H., Di Battista J.A., Pelletier J.P., Mineau F., Ranger P., Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum. 2001, 44:595-607.
13. Fahmi H., Pelletier J.P., Di Battista J.A., Cheung H.S., Fernandes J.C., Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. Osteoarthritis Cartilage 2002, 10:100-108.
14. Fahmi H., Pelletier J.P., Martel-Pelletier J. PPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview. J. Rheumatol. 2002, 29:3-14.
15. Felson D.T., Zhang Y. An update on the epidemiology of knee and hiposteoarthritis with a view to prevention. Arthritis Rheum. 1998, 41:1343-1355.
16. Felson D.T., Lawrence R.C., Dieppe P.A., Hirsch R., Helmick C.G., Jordan J.M., Kington R.S., Lane N.E., Nevitt M.C., Zhang Y., Sowers M., McAlindon T., Spector T.D., Poole A.R., Yanovski S.Z., Ateshian G., Sharma L., Buckwalter J.A., Brandt K.D., Fries J.F. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann. Intern. Med. 2000, 133:635-646.
17. Feydy A., Pluot E., Guerini H., Drapé J.L. Osteoarthritis of the wrist and hand, and spine. Radiol. Clin. North Am. 2009, 47:723-759.
18. François M., Richette P., Tsagris L., Raymondjean M., Fulchignoni-Lataud M.C., Forest C., Savouret J.F., Corvol M.T. Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element. J. Biol. Chem. 2004, 279:28411-28418.
19. Goldring M.B., Goldring S.R. Osteoarthritis. J. Cell. Physiol. 2007, 213:626-634.
20. Holt I., Cooper R.G., Hopkins S.J. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur. J. Clin. Invest. 1991, 21:479-484.
21. Kobayashi T., Notoya K., Naito T., Unno S., Nakamura A., Martel-Pelletier J., Pelletier J.P. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum. 2005, 52:479-487.
22. Lander M., Tauras J.M., Ogiste J.S., Hori O., Moss R., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272:17810-17814.
23. Lawrence R.C., Helmick C.G., Arnett F.C., Deyo R.A., Felson D.T., Giannini E.H., Heyse S.P., Hirsch R., Hochberg M.C., Hunder G.G., Liang M.H., Pillemer S.R., Steen V.D., Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998, 41:778-799.
24. Loeser R.F., Yammani R.R., Carlson C.S., Chen H., Cole A., Im H.J., Bursch L.S., Yan S.D. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum. 2005, 52:2376-2385.
25. Nah S.S., Choim I.Y., Yoo B., Kim Y.G., Moon H.B., Lee C.K. Advanced glycation end products increases matrix metalloproteinase-1,-3, and-13, andTNF-alpha in human osteoarthritic chondrocytes. FEBS Lett. 2007, 581:1928-1932.
26. Rasheed Z., Anbazhagan A.N., Akhtar N., Ramamurthy S., Voss F.R., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-α and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res. Ther. 2009, 11:R71.
27. Reiser K.M. Nonenzymatic glycation of collagen in aging and diabetes. Proc. Soc. Exp. Biol. Med. 1998, 218:23-37.
28. Schmidt I.S., Yan S.D., Stern D.M. The dark side of glucose. Nat. Med. 1995, 1:1002-1004.
29. Steenvoorden M.M., Huizinga T.W., Verzijl N., Bank R.A., Ronday H.K., Luning H.A., Lafeber F.P., Toes R.E., DeGroot J. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum. 2006, 54:253-256.
30. Tomasek J.J., Meyers S.W., Basinger J.B., Green D.T., Shew R.L. Diabetic and age-related enhancement of collagen-linked fluorescence in cortical bones of rats. Life Sci. 1994, 55:855-861.
31. Valencia J.V., Weldon S.C., Quinn D., Kiers G.H., DeGroot J., TeKoppele J.M., Hughes T.E. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal. Biochem. 2004, 324:68-78.
32. Yammani R.R., Carlson C.S., Bresnick A.R., Loeser R.F. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum. 2006, 54:2901-2911.
33. Yan S.D., Schmidt A.M., Anderson G.M., Zhang J., Brett J., Zou Y.S., Pinsky D., Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 1994, 269:9889-9897.